Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Niacin/Lovastatin Prescribers for Hyperlipidemia

Analysis of: Drugs to Build Bones May Weaken Them (www.nytimes.com)
 Should bisphosphonates be stopped in patients who have been taking them for many years?  Should they be used at all?
Analysis of: New data show Tekturna HCT® is twice as effective at reducing blood pressure than the diuretic HCT alone (www.novartis.com)
It is well known that the addition of thiazide diuretic to ACEI or ARB treatment adds about 10 mm Hg reduction on top of the 10 mm Hg reduction provided by the ACEI or ARB agent.  It is expected that blocking renin in the renin angiotensin system with Tekturna would provide a similar result.
Analysis of: Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration (www.pipelinereview.com)
TRITON-TIMI 38 study of 13,608 patients with ACS compared prasugrel against clopidogrel, combined with aspirin.  Prasugrel reduced the combined rate of CV death, MI or stroke (12.1% for clopidogrel vs. 9.9% for prasugrel). The benefit came at a cost of increased serious bleeding (1.4%, vs....
Dan Streja, MD, Clinical Professor of Medicine
University of California, Los Angeles
Analysis of: No right to experimental drugs for dying patients: Supreme Court (news.yahoo.com)
The Supreme Court has rejected the use of experimental drugs by the dying patients on the grounds that "The framers (of the US constitution) understood that the pursuit of life is an inalienable right that should not be abridged without due process of law." Over the years our patients with terminal...
Analysis of: Schering releases ENHANCE data today (www.tradingmarkets.com)
Physicians have several possible conclusions that can be taken; These include: - the trial is flawed - the selection of patients with much less CIMT than previous trials such as ASAP and ARBITER flaws the study -  the failure to meet the trial endpoint is only a surrogate and clinical trial data...
Howard Weintraub, MD, Clinical Director
New York University Medical Center
Analysis of: Ranexa(R) Significantly Reduces Incidence Of CV Death, MI Or Recurrent Ischemia In MERLIN TIMI-36 Patients With Elevated BNP (www.medicalnewstoday.com)
By restoring function in the late Na channel and hence improving diastolic function (amongst other things), Ranexa has worked terrifically in my patients with any evidence for diastolic dysfunction. This typically manifests with shortness of breath and can be associated with an elevated level...
Howard Weintraub, MD, Clinical Director
New York University Medical Center
November 8, 2007
Even more benefit.
Analysis of: Ranexa(R) Significantly Reduces Incidence Of CV Death, MI Or Recurrent Ischemia In MERLIN TIMI-36 Patients With Elevated BNP (www.medicalnewstoday.com)
The good news gets better as there is now data from MERLIN that corroborates the news from CARISA showing a reduction in HbGA1C that was significant.
Analysis of: Liraglutide improves glucose control and lowers body weight in two phase 3 studies comprising more than 2,000 patients (www.pipelinereview.com)
The fewer the injections, the more market share if all else is the same. We will await to see how needle size will affect LAR acceptance. My estimate is that it will absolutely not. Patients never asked what the size of the needle was prior to initiation of BYETTA bid--they just heard "weight loss and...
Analysis of: Elixir Pharmaceuticals initiates final Phase III clinical study prior to NDA (www.pipelinereview.com)
OADs such as sulfonylureas and glitinides are being displaced today with the advent of sitagliptin for those who have coverage for this medication.
Analysis of: SYMLIN(R) Used in Conjunction with Basal Insulin in Patients with Type 2 Diabetes (www.pipelinereview.com)
Too much hastle for too little benefit

Page : 1 2 Next1 to 10 of 19

Analytics


Generated at 2009-01-07T19:00:58.307